TCIM
BCRX icon

TIAA CREF Investment Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

TIAA CREF Investment Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$4.16M Buy
510,408
+1,900
+0.4% +$16.3K ﹤0.01% 1567
2018
Q4 		$4.1M Buy
508,508
+3,402
+0.7% +$26.5K ﹤0.01% 1506
2018
Q3 		$3.85M Sell
505,106
-33,189
-6% -$223K ﹤0.01% 1751
2018
Q2 		$3.08M Sell
538,295
-9,851
-2% -$54.2K ﹤0.01% 1933
2018
Q1 		$2.62M Sell
548,146
-1,255
-0.2% -$6.45K ﹤0.01% 1960
2017
Q4 		$2.7M Buy
549,401
+47,471
+9% +$230K ﹤0.01% 1968
2017
Q3 		$2.63M Buy
501,930
+33,048
+7% +$169K ﹤0.01% 2011
2017
Q2 		$2.61M Buy
468,882
+116,782
+33% +$711K ﹤0.01% 2025
2017
Q1 		$2.96M Sell
352,100
-7,922
-2% -$55.1K ﹤0.01% 1907
2016
Q4 		$2.28M Sell
360,022
-25,317
-7% -$132K ﹤0.01% 2117
2016
Q3 		$1.7K Sell
385,339
-2,811
-0.7% -$11.2K ﹤0.01% 2260
2016
Q2 		$1.1M Buy
388,150
+61,277
+19% +$190K ﹤0.01% 2457
2016
Q1 		$925K Hold
326,873
– – ﹤0.01% 2515
2015
Q4 		$3.37M Sell
326,873
-10,844
-3% -$108K ﹤0.01% 1825
2015
Q3 		$3.85M Sell
337,717
-13,014
-4% -$174K ﹤0.01% 1718
2015
Q2 		$5.24M Sell
350,731
-2,307
-0.7% -$26.2K ﹤0.01% 1651
2015
Q1 		$3.19M Buy
353,038
+484
+0.1% +$5.01K ﹤0.01% 1931
2014
Q4 		$4.29M Sell
352,554
-15,600
-4% -$172K ﹤0.01% 1731
2014
Q3 		$3.6M Buy
368,154
+16,926
+5% +$207K ﹤0.01% 1840
2014
Q2 		$4.48M Buy
+351,228
New +$3.42M ﹤0.01% 1765
2013
Q3 		– Sell
-4,886
Closed -$8K – 3094
2013
Q2 		$8K Buy
+4,886
New +$8.43K ﹤0.01% 3094

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

TIAA CREF Investment Management's BCRX Position: Q1 2019 in Review

TIAA CREF Investment Management increased its BioCryst Pharmaceuticals (BCRX) stake by 0.37% in Q1 2019, buying an estimated $16.3K and bringing the position to 510,408 shares worth $4.16M. The position accounts for ﹤0.01% of the portfolio, ranked #1567.

TIAA CREF Investment Management first reported a position in BCRX in Q2 2013 and has held it in 21 quarters since. The position peaked at $5.24M in Q2 2015. 133 funds tracked by Wall St. Rank hold BCRX as of Q1 2019.

  • TIAA CREF Investment Management held 510,408 shares of BioCryst Pharmaceuticals worth $4.16M as of Q1 2019.
  • TIAA CREF Investment Management bought 1,900 BioCryst Pharmaceuticals shares in Q1 2019, an estimated $16.3K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #1567 holding.
  • TIAA CREF Investment Management first reported a position in BioCryst Pharmaceuticals in Q2 2013 and has held it in 21 quarters since.
  • TIAA CREF Investment Management's BioCryst Pharmaceuticals position peaked at $5.24M in Q2 2015.
  • 133 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.